Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nyxoah ( (NYXH) ) just unveiled an update.
Nyxoah announced the commercial launch of its Genio therapy in the Middle East, with the first successful implantation at the Saudi German Hospital in Dubai. This launch marks a significant milestone as the first neurostimulation therapy for OSA in the region, offering new treatment options for patients who do not tolerate CPAP. The company aims to expand access to Genio globally, enhancing its market position and offering hope to OSA patients.
More about Nyxoah
Nyxoah is a medical technology company focused on developing innovative therapeutic alternatives for obstructive sleep apnea (OSA) using neuromodulation. The company’s flagship product, Genio, is a battery-free hypoglossal neuromodulation device that addresses OSA and is gaining global traction. Nyxoah has received CE mark approval in Europe and is working towards FDA approval in the United States.
YTD Price Performance: 16.48%
Average Trading Volume: 45,517
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $374.3M
Find detailed analytics on NYXH stock on TipRanks’ Stock Analysis page.
